Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis

Tsampasian, Vasiliki, Elghazaly, Hussein, Chattopadhyay, Rahul Kumar, Ali, Omar, Corballis, Natasha, Chousou, Panagiota Anna, Clark, Allan ORCID: https://orcid.org/0000-0003-2965-8941, Garg, Pankaj ORCID: https://orcid.org/0000-0002-5483-169X and Vassiliou, Vassilios ORCID: https://orcid.org/0000-0002-4005-7752 (2022) Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 29 (6). e227–e229. ISSN 2047-4873

Preview	PDF (F1. CV death or HHF) - Accepted Version Download (291kB) | Preview
Preview	PDF (Accepted_Manuscript) - Accepted Version Download (172kB) | Preview
Preview	PDF (SupplMaterial_Updated) - Accepted Version Download (513kB) | Preview
	Microsoft Word (OpenXML) (Table_updated) - Accepted Version Download (15kB)

Abstract

Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.

Item Type:	Article
Uncontrolled Keywords:	epidemiology,cardiology and cardiovascular medicine ,/dk/atira/pure/subjectarea/asjc/2700/2713
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	28 Oct 2021 00:49
Last Modified:	01 Dec 2022 01:38
URI:	https://ueaeprints.uea.ac.uk/id/eprint/81902
DOI:	10.1093/eurjpc/zwab189

Actions (login required)

View Item